The Ivan Maillard Lab
Research

Research in my laboratory is uncovering new functions of the Notch signaling pathway in immune regulation and malignant transformation, with a focus on T and B lymphocytes in secondary lymphoid organs.
Projects
- Notch signaling in alloimmunity
Publications Highlights
Zhang Y, Sandy AR, Wang J, Shan GT, Radojcic V, Tran I, Friedman A, Kato K, He S, Cui S, Hexner E, Frank D, Emerson SG, Pear WS, Maillard I. Notch signaling is a critical regulator of allogeneic CD4+ T cell responses mediating graft-versus-host disease. Blood, 117(1): 299-308, 2011. PMCID: PMC3037751
Tran IT, Sandy AR, Carulli AJ, Ebens C, Chung J, Shan GT, Radojcic V, Friedman A, Gridley T, Shelton A, Reddy P, Samuelson LC, Yan M, Siebel CW, Maillard I. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest, 123(4): 1590-1604, 2013. PMCID: PMC3613915
Chung J, Ebens CE, Perkey E, Radojcic V, Koch U, (…), Friedman A, Granadier D, Tran IT, Chai Q, Onder L, Yan M, Reddy P, Blazar BR, Huang AY, Brennan TV, Bishop DK, Ludewig B, Siebel CW, Radtke F, Luther SA, Maillard I. Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. J Clin Invest, 127(4): 1574-88, 2017. PMCID: PMC5373885
Gómez Atria D*, Gaudette BT*, Londregan J*, Kelly S, Perkey E, Allman A, Srivastava B, Koch U, Radtke F, Ludewig B, Siebel CW, Ryan RJH, Robertson TF, Burkhardt JK, Pear WS, Allman D**, Maillard I**. Stromal Notch ligands foster lymphopenia-driven functional plasticity and homeostatic proliferation of naïve B cells. J Clin Invest, 2022 Jul 1;132(13):e158885. doi: 10.1172/JCI158885. PMCID: PMC9246379.
Tkachev V*, Vanderbeck A*, Perkey E*, Furlan SN, McGuckin C, Gómez Atria D, Gerdemann U, Rui X, Lane J, Hunt DJ, Zheng H, Colonna L, Hoffman M, Yu A, Outen R, Kelly S, Allman A, Burbach B, Shimizu Y, Panoskaltsis-Mortari, Chen G, Carpenter SM, Harari O, Kuhnert F, Thurston G, Blazar BR, Kean LS**, Maillard I**. Notch signaling drives intestinal graft-versus-host disease in mice and non-human primates. Science Translational Medicine15(702):eadd175, 2023. PMID: 37379368.
People

Ivan Maillard, MD, PhD
- New roles for Notch signaling in the immune system.
- maillai@mskcc.org
- Email Address
Members

- BS, UCLA
- Cancer Engineering
Lab Manager

GSK Student
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ivan Maillard discloses the following relationships and financial interests:
-
Garuda Therapeutics
Professional Services and Activities
-
Sanofi US Services Inc.
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.